Late-Breaking Abstract on LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibito...
March 09 2017 - 9:35AM
ADVFN NewsWire
Late-Breaking Abstract on LB-100, Lixte Biotechnology's Protein
Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in
an Animal Model to be Presented at the AACR Annual Meeting
EAST SETAUKET, NY-(Marketwired - Mar 9, 2017) - Lixte
Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that a late-breaking abstract
entitled "Protein phosphatase 2A inhibition with a novel small
molecule inhibitor, LB-100, achieves durable immune-mediated
antitumor activity when combined with PD-1 blockade in a
preclinical model" has been accepted for presentation as a poster
(abstract number LB-193) at the American Association for Cancer
Research Annual Meeting 2017 in Washington, DC on April 4th.
Dr. John S. Kovach, Founder and CEO of Lixte, said, "The new
preclinical research studies were done by Lixte and scientists at
the National Institute of Neurological
Disorders and Stroke (NINDS), National Institutes of Health
(NIH), under a Cooperative Research and Development Agreement." Dr.
Kovach continued, "LB-100 used alone has recently completed a Phase
1 trial in patients with advanced cancer (Chung 2016)."
About Lixte Biotechnology Holdings, Inc.
Lixte is a drug discovery company that uses biomarker technology to
identify enzyme targets associated with serious common diseases and
then design novel compounds to attack those targets. Lixte's
product pipeline encompasses two major categories of compounds at
various stages of pre-clinical and clinical development that the
Company believes have broad therapeutic potential not only for
cancer but also for other debilitating and life-threatening
diseases.
Forward-Looking Statements
This announcement contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933,
and Section 21E of the Securities Exchange Act of 1934. For
example, statements regarding the Company's financial position,
business strategy and other plans and objectives for future
operations, and assumptions and predictions about future product
demand, supply, manufacturing, costs, marketing and pricing factors
are all forward-looking statements. These statements are generally
accompanied by words such as "intend," anticipate," "believe,"
"estimate," "potential(ly)," "continue," "forecast," "predict,"
"plan," "may," "will," "could," "would," "should," "expect" or the
negative of such terms or other comparable terminology. The Company
believes that the assumptions and expectations reflected in such
forward-looking statements are reasonable, based on information
available to it on the date hereof, but the Company cannot provide
assurances that these assumptions and expectations will prove to
have been correct or that the Company will take any action that the
Company may presently be planning. However, these forward-looking
statements are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission at
http://www.sec.gov/edgar.shtml.
Additional information on the Company is available at www.lixte.com.
Contact Information
Eric J. Forman, Esq.
646-894-3135
eforman@lixte.com